Mainboard · BSE and NSEDraft filed

IBERIA PHARMACEUTICALS INDIA LIMITED IPO: dates, price band, lot size, objects of the issue

Get updates on this IPO

Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.

Dates, allotment, listing and analyst views. Stop anytime.

By continuing you agree to the Terms and Privacy policy

Updated Sun 15 Nov 2026, 8:04 pm IST · Source: DRHP dated Sat 5 Sep 2026

Key facts

Price band
Not announced
Lot size
Not announced
Lot amount at the upper band
Not announced
Issue size at the upper band
64,75,560 shares (Amount not stated in the draft)
DRHP dated Sat 5 Sep 2026, page 1
Fresh issue
64,75,560 shares (Amount not stated in the draft)
DRHP dated Sat 5 Sep 2026, page 1
Offer for sale
None
DRHP dated Sat 5 Sep 2026, page 1
Bid dates
Not announced
Listing date
Not announced
Risk factors
Not announced
Proposed exchanges
BSE and NSE

Timeline (IST)

  1. Draft filedThu 17 Sep 2026 confirmedDRHP dated Sat 5 Sep 2026
  2. OpensDates to be announced
  3. ClosesDates to be announced
  4. AllotmentDates to be announced
  5. Refund and unblockDates to be announced
  6. ListingDates to be announced

Objects of the issue

ObjectAmount
Capital expenditure towards the procurement of plant & machinery for the establishment of our manufacturing facility in Haryana, India₹34.90 crore
Repayment of all or a portion of certain outstanding borrowings availed by our Company₹12.00 crore
Branding and marketing expenses towards enhancing the awareness and visibility of our products and brand₹16.90 crore
Funding the working capital requirements of our Company₹31.00 crore
General Corporate PurposesNot stated in the draft
TotalNot stated in the draft

DRHP dated Sat 5 Sep 2026, page 109

Company and promoters

As described in the DRHP

We are an Indian pharmaceutical and derma cosmetics company with a select portfolio of products across aesthetic dermatology, hair care, cardio diabetic and general therapeutics, offering solutions for a wide range of skin, hair, cardiovascular, diabetic and anti-aging concerns.

DRHP dated Sat 5 Sep 2026, page 195

Promoters

  • 4 individual promoters

DRHP dated Sat 5 Sep 2026, page 277

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group97.59%Not stated in the DRHP

DRHP dated Sat 5 Sep 2026, page 104

Financials (restated)

ItemMarch 31, 2026March 31, 2025March 31, 2024
Revenue from operations₹96.54 crore₹86.72 crore₹69.36 crore
Profit after tax₹11.13 crore₹14.19 crore₹7.82 crore
Net worth₹51.65 crore₹39.95 crore₹14.62 crore
Total borrowingsNot stated in the draftNot stated in the draftNot stated in the draft

DRHP dated Sat 5 Sep 2026, page 79

Peer comparison (as in the DRHP)

Name of the CompanyFace Value (₹ per share)Closing Price as on September 02, 2026 (₹ per share)Revenue from operations for Financial Year 2026 (in ₹ Lakhs)Basic Earnings per share for Financial Year 2026(₹)(1)Net Asset Value per Equity share as on March 31, 2026(2)P/ E Ratio for the Financial year 2026(3)Return on capital employed for the Financial year 2026(4)
Iberia Pharmaceuticals India Limited10.00NA9,653.75.7326.59NA19.85
Eris Lifesciences Limited1.001,3353,12,94245.33281.6429.4514.1
Torrent Pharmaceuticals Limited5.005,004.0013,98,00063.92247.8778.2915.2

Reproduced from the DRHP dated Sat 5 Sep 2026, page 136; InsightPier adds no figures

Risk factors

  1. Most revenue comes from the top two brands (DRHP page 27)
  2. Business depends on exclusive distribution arrangements with brand owners and suppliers (DRHP page 28)
  3. The company makes none of its products and relies on third-party manufacturers (DRHP page 29)
  4. Distributing imported products exposes the company to liability and regulatory risks (DRHP page 31)
  5. Supply disruptions or cost increases for raw materials and finished products could hurt the business (DRHP page 31)

Offer document

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts